Previous studies have reported that the mutation of the TP53 gene is related to the poor therapeutic effect and prognosis of BC (54, 55), confirming the poor prognosis of patients with a high TP53 mutation rate in our high-risk group. The gene discussed is TP53; the disease is breast cancer.